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Background: Meaning‐centered group psychotherapy for cancer survivors (MCGP‐
CS) improves meaning, psychological well‐being, and mental adjustment to cancer and
reduces psychological distress. This randomized controlled trial was conducted to
investigate the cost‐utility of MCGP‐CS compared with supportive group psychother-
apy (SGP) and care‐as‐usual (CAU).
Methods: In total, 170 patients were randomized to MCGP‐CS, SGP, or CAU. Inter-
vention costs, direct medical and nonmedical costs, productivity losses, and health‐
related quality of life were measured until 6 months follow‐up, using the TIC‐P,
PRODISQ, data from the hospital information system, and the EQ‐5D. The cost‐utility
was calculated by comparing mean cumulative costs and quality‐adjusted life years
(QALYs).
Results: Mean total costs ranged from €4492 (MCGP‐CS) to €5304 (CAU). Mean
QALYs ranged .507 (CAU) to .540 (MCGP‐CS). MCGP‐CS had a probability of 74%
to be both less costly and more effective than CAU, and 49% compared with SGP.
Sensitivity analyses showed these findings are robust. If society is willing to pay €0
for one gained QALY, MCGP‐CS has a 78% probability of being cost‐effective com-
pared with CAU. This increases to 85% and 92% at willingness‐to‐pay thresholds of
€10 000 and €30 000, which are commonly accepted thresholds.
Conclusions: MCGP‐CS is highly likely a cost‐effective intervention, meaning that
there is a positive balance between the costs and gains of MCGP‐CS, in comparison
with SGP and CAU.
KEYWORDS
cancer, cost‐effectiveness, cost‐utility analysis, existential, group psychotherapy, MCGP, meaning,
meaning‐centered psychotherapy, oncology, psychotherapy1 | INTRODUCTION
Due to continuing innovations in the detection and treatment of
cancer, more and more cancer patients become long‐term survivors.1ty.
td. wileyonlinelibHowever, often cancer survivorship comes with long‐lasting hin-
drances in the patient's life, such as limitations of activities in daily liv-
ing, physical limitations, work‐related problems, and psychological
problems.2 Several interventions have been shown to be effective in
improving these problems, including psychological interventions.3
Carlson and Bultz4 argued that psychological treatment is effectivePsycho‐Oncology. 2018;27:1772–1779.rary.com/journal/pon
VAN DER SPEK ET AL. 1773and potentially leads to a decrease in health care use in cancer
patients and may therefore be a corner stone in cost‐effective cancer
care, to meet the growing need for psychosocial oncology care. How-
ever, economic evaluations of psychosocial interventions for cancer
patients altogether are scarce.5
Meaning‐centered group psychotherapy (MCGP) was developed
to sustain or enhance a sense of meaning in advanced cancer patients
and has shown to be effective in increasing spiritual well‐being and
quality of life and reducing hopelessness, depression, and desire for
hastened death.6
Recently, a randomized controlled trial was conducted to evaluate
the efficacy of meaning‐centered group psychotherapy for cancer sur-
vivors (MCGP‐CS).7 This study showed that MCGP‐CS, compared
with supportive group psychotherapy (SGP) and care‐as‐usual (CAU),
was effective in improving sense of meaning, psychological well‐being,
and mental adjustment to cancer, and to reduce psychological distress
up until 6 months after intervention. The evidence of beneficial effects
of meaning‐focused interventions is growing,6,8-12 yet no studies have
been performed from an economical perspective. A cost‐utility analy-
sis (CUA) is a method that analyses the ratio between the costs and
the gains of an intervention. The gains in these analyses are expressed
as quality‐adjusted life years (QALYs), meaning the number of years
with improved quality of life for an individual that are gained because
of the intervention. The outcomes of CUAs are used, by, for instance,
policy makers, as a tool to compare health care interventions in terms
of costs and benefits. The aim of the present study was to evaluate
the cost‐utility of MCGP‐CS in comparison with SGP and CAU among
cancer survivors, within the context of a randomized trial (RCT).2 | METHODS
2.1 | Setting and participants
The trial was performed in the Netherlands from August 2012 to May
2015; approval was obtained from the Medical Ethical Committee of
the Leiden University Medical Center. Participants were recruited via
hospitals and public media. Inclusion criteria were cancer diagnosis in
the last 5 years, treated with curative intent, main treatment com-
pleted, ability to attend all therapy sessions, expressed need for psy-
chological help/support, and at least one psychosocial complaint (eg,
depressed mood, anxiety, coping issues, life questions, meaning mak-
ing problems, and relationship problems). Exclusion criteria were
severe cognitive impairment, current psychological treatment, and
insufficient mastery of Dutch language. The study protocol and results
on the efficacy of MCGP‐CS were published elsewhere.7,132.2 | Design and randomization
Economic data were collected alongside the RCT at baseline, and at 3
and 6 months follow‐up.7,13 This study was a 3‐study arm RCT with
computer‐generated block randomization that was prepared by an
independent researcher. Participants were allocated to a group. When
the group counted between 7 and 10 survivors, the group was ran-
domly assigned by the independent researcher using a list of sequen-
tially numbered allocations to one of the 3 study arms. Participantsand psychotherapists were aware of the allocated arm, whereas data
managers were blinded to the allocation.2.3 | Meaning‐centered group psychotherapy for
cancer survivors
The experimental study arm was MCGP‐CS, a manualized 8‐week
group intervention that makes use of didactics, group discussion, and
experiential exercises that focus around themes related to meaning
and cancer survivorship. This intervention is an adaptation of MCGP
for advanced cancer patients. The sessions took 2 hours each and
were held weekly; most sessions address a source of meaning, eg, cre-
ativity as source of meaning. The participants used a workbook and
received homework assignments every week. MCGP‐CS was led by
a psychotherapist with experience in treating patients with cancer.
The main purpose of the MCGP‐CS is to sustain or enhance a sense
of meaning or purpose in the patient's life, in order to cope better with
the consequences of cancer.2.4 | Supportive group psychotherapy
The control condition is an 8‐week social support group, which does
not focus on meaning.14 The sessions took 2 hours and were held
weekly; each session focusses on a relevant topic for survivors, such
as vocational issues, coping with family and friend, and body image.
Each group was supervised by a psychotherapist with experience in
treating patients with cancer. The psychotherapist had an uncondi-
tionally positive regard and emphatic understanding, stimulated
patients to actively share their experiences, and focused on positive
emotions, and expression of feelings.2.5 | Care‐as‐usual
Participants in the CAU study arm did not participate in one of the
group interventions. If a patient in the CAU study arm asked for psy-
chological help after allocation, he or she was referred to their general
practitioner (GP).2.6 | Outcome assessment
Patient Reported Outcome Measures (PROMs) measuring the efficacy
of MCGP‐CS were collected at all time points: baseline (T0), after
1 week (T1), 3 months (T2), and 6 months (T3). Cost evaluation out-
comes were collected at T0, T2, and T3.
Direct medical and direct nonmedical cost data were collected
with the Trimbos and iMTA questionnaire on Costs associated with
Psychiatric illness (TiC‐P).15 TheTiC‐P measures the use of healthcare
facilities (eg, number of visits to the GP) and other facilities (eg, partic-
ipation in self‐help groups or use of informal care) in the past 4 weeks,
and medication use (ie, antidepressants, painkiller, and sedative) in the
past 2 weeks. In addition, healthcare utilization within the hospital
during the study (ie, visits to the medical specialist, day treatment,
and hospital admission) was collected using the hospital information
system. Unit resource use (GP visits, hospital days, etc) was multiplied
by their appropriate integral cost prices.16 Traveling costs to health
care services, including parking costs, were calculated by multiplying
1774 VAN DER SPEK ET AL.unit resource use by average distance to the location (eg, GP or hospi-
tal) times the price per km. All prices were adjusted to 2014 prices
using the consumer price index.
Productivity losses through lost workdays (absenteeism) and
reduced quantity or quality of performed paid work (presenteeism)
were sampled with the appropriate modules of the Productivity and
Disease Questionnaire (PRODISQ).17 Productivity losses due to
presenteeism was calculated by multiplying the days of less productiv-
ity at work by the estimated amount of lost quantity or quality of the
performed work (ranging from 0 to 10 on a 10‐point scale). Indirect
no‐medical costs due to absenteeism and presenteeism were calcu-
lated by multiplying productivity losses by respectively age and gender
specific costs16 using the human capital approach.
Health‐related quality of life was assessed with the EuroQoL‐5D
(EQ‐5D); the utility score was obtained using the Dutch index
tariff.18,192.7 | Intervention costs
Intervention costs were calculated using a bottom‐up approach. The
costs of MCGP‐CS per patient consisted of costs for intake by a psy-
chotherapist (€21.98), direct time of a psychotherapist for the provi-
sion of eight 2‐hour MCGP‐CS sessions in groups of 8 (€175.87 per
patient), indirect time of a psychotherapist of 1 hour per MCGP‐CS
session (€87.94 per patient), and costs of a workbook (€2.50). The
costs of supportive group psychotherapy (SGP) were similar, minus
the workbook costs. Total costs per patient were €288 for patients
in the MCGP‐CS group and €286 for patients in the SGP group.2.8 | Statistical analyses
All analyses were performed using the IBM Statistical Package for the
Social Science version 22 (IBM Corp, Armonk, NY, USA) and STATA ver-
sion 12.1 (StataCorp LP, Texas, USA). Descriptive statistics were used to
describe patient characteristics, costs, and EQ‐5D utility scores.
To assess the cost‐utility of MCGP‐CS compared with SGP and
with CAU, and the cost‐utility of SGP compared with CAU, a base case
intention‐to‐treat CUA was performed including all 170 patients.
Missing data were imputed as total costs or utility score per time point
per treatment arm using multiple imputation (predictive mean
matching) by chained equations. Data were imputed only for those
time points that were missing. Linear and logistic regression analyses
were performed to investigate which variables (socio‐demographic,
clinical and several PROMs used for measuring the efficacy of
MCGP‐CS13) were associated with missing data, observed costs or
EQ‐5D utility scores. Variables that were found to be associated with
missing data (Life Orientation Test‐Revised total score), total cost
(work situation, cancer type, time since last treatment, age, and MAC
fighting spirit), or EQ‐5D utility score (work situation, history of psy-
chological treatment, gender, and Personal Meaning Profile (PMP)
total score) were included in the multiple imputation model. In addi-
tion, variables found to differ statistically between the treatment
groups at baseline (gender, The Ryff Scales of Psychological Well‐
Being (SPWB) positive relations, and spiritual change) were included
in the multiple imputation model. Ten imputed datasets were createdand analyzed separately. Results of the 10 analyses were pooled using
Rubin's (1987) rules.20
Subsequently, cumulative costs and QALYs per patient were cal-
culated. Costs between T0 and T3, as measured using the TIC‐P and
PRODISQ, were calculated for the 3 groups using linear interpolation,
by summing costs in the last 4 weeks at time point T0 and multiplying
by 2 for the time periodsT0 toT1 (8 weeks), and summing the costs in
the last 4 weeks at time points T2 and T3, multiplying by their corre-
sponding time period of 3 months (respectively, T1 to T2 and T2 to
T3). Total cumulative costs per patient were calculated by summing
costs measured using theTIC‐P and PRODISQ with intervention costs
and costs measured using the hospital information system. The num-
ber of QALYs per patient was calculated by multiplying the EQ‐5D
utility score by the appropriate time period it accounts for using linear
interpolation, with the same calculation as the cumulative costs.
An incremental cost‐utility ratio for each of the comparisons
(MCGP‐CS vs CAU; MCGP‐CS vs SGP; SGP vs CAU) was calculated
by dividing the incremental costs by the incremental effects using
the following formula: (mean Costs intervention − mean Costs compara-
tor)/(mean QALYs intervention − mean QALYs comparator).
To study the impact of uncertainty on the cost and QALY esti-
mates per treatment group, we used bootstrapping with 5000 replica-
tions. The results were projected on a cost‐utility plane. In the cost‐
utility plane, we depicted the incremental costs between conditions
(MCGP‐CS vs CAU; MCGP‐CS vs SGP; SGP vs CAU), on the y‐axis,
while the incremental QALYs were presented on the x‐axis, resulting
in 4 different quadrants. The northeast quadrant indicates that the
intervention is more expensive and more effective compared with
the control group, the southeast (SE) quadrant indicates that the inter-
vention is less expensive and more effective, the southwest quadrant
indicates that the intervention is less expensive and less effective, and
finally, the northwest quadrant indicates that the intervention is more
expensive and less effective. When the intervention is more effective
but at additional costs (northeast quadrant), a trade‐off has to be made
between gained QALYs and additional costs. A cost‐utility acceptabil-
ity curve was therefore plotted, which presents the probability that
the intervention is cost‐effective compared with the control group
for different willingness‐to‐pay thresholds for one QALY gained.
To assess the robustness of the findings of the base case analysis,
3 additional analyses were performed: (1) a complete cases CUA
including only patients with complete data at all time points; (2) an
intention to treat analysis in which costs and quality of life measured
at T2 were hypothesized to be representative for the time periods
T0 to T2 (instead of the T0 measurement in the base case intention‐
to‐treat analyses); and (3) an analysis in which we investigated
whether adjusting for variables at baseline (total costs at baseline,
EQ‐5D score at baseline, gender, SPWB positive relations, spiritual
change, and employment status) had a major impact (a change of
≥20%) on incremental costs or incremental effects.3 | RESULTS
Of the 184 eligible participants, 170 completed the baseline question-
naire and were randomly assigned to MCGP‐CS (n = 57), SGP (n = 56),
VAN DER SPEK ET AL. 1775or CAU (n = 57). There were no significant differences between the 3
groups, except for more males in the MCGP‐CS condition (Table 1). In
the SGP group, 1 patient deceased after randomization, but before the
start of the intervention.3.1 | Direct and indirect medical costs and
productivity costs
In the 4 weeks prior to baseline assessment (T0), the total mean costs
in the MCGP‐CS group were €521 (SD = 1185), in the SGP group
€478 (SD = 670), and in the CAU group €550 (SD = 1007) (P = .93).
In all 3 groups, the productivity costs were the largest expense. For
the mean costs per time point per study arm of the study participants,
see Table S1.TABLE 1 Participant characteristics
MCGP‐C
Age, mean (SD) 58.6 (10







No religion 34 (60
Marital status, single N (%) 12 (21
Work situation
Paid job 26 (46
No paid job/retired 30 (54
Household composition
Lives alone 10 (18
Lives with partner 28 (49
Lives with children 2 (4%





Months since last cancer treatment median (range) 19 (6‐5
Type of treatment
Chemotherapy, N (%) 26 (53
Surgery, N (%) 57 (10
Radiation, N (%) 31 (54
Hormonal therapy, N (%) 22 (30
History psychological treatment, N (%)
Received psychological treatment in the last year 12 (21
Received psychological treatment >1 y ago 21 (37
Never received psychological treatment before 24 (42
Significant negative event in past 2 y other than cancer, N (%) 27 (47
aKruskall Wallis.
bSignificant difference between MCGP‐CS and CAU.3.2 | Health‐related quality of life
There was no statistically significant difference in the EQ‐5D utility
scores between the 3 conditions at baseline (P = .99). For the mean
EQ‐5D utility scores per group per time point, see Table S1.3.3 | Cost‐utility analyses
Table 2 shows the results of the base case intention‐to‐treat CUA
with imputed data (n = 170). There was no statistically significant
difference in costs and QALYs between the 3 conditions. When
comparing MCGP‐CS to CAU, the incremental costs were €−812
(95% CI, −2830 to 1350), and the incremental effects were .033
(95% CI, −.007 to .074). The uncertainty surrounding this finding
was assessed using bootstrapping and projected on a cost‐utility planeS (n = 57) SGP (n = 56) CAU (n = 57) P χ2
.7) 55.5 (9.6) 57.3(10.4) .340 2.58
%)b 49 (88%) 51 (90%) .012 8.83
.156 6.65
%) 9 (16%) 17 (30%)
%) 25 (45%) 14 (26%)
%) 22 (39%) 25 (44%)
.181 3.42
%) 32 (57%) 30 (53%)
%) 24 (43%) 27 (47%)
%) 9 (16%) 13 (23%) .650 0.86
%) 31 (57%) 31 (56%) .441 1.64
%) 23 (43%) 24 (44%)
%) 11 (20%) 11 (19%)
%) 27 (48%) 21 (37%)
) 1 (2%) 3 (5%)
%) 17 (30%) 22 (39%)
.071 8.63
%) 40 (71%) 42 (74%)
%) 12 (21%) 10 (18%)
%) 4 (7%) 5 (9%)
8) 16 (5‐52) 18 (3‐55) .888 0.24a
%) 34 (61%) 36 (67%) .124 4.18
0%) 56 (100%) 56 (98%) .369 1.99
%) 32 (57%) 33 (58%) .924 0.16
%) 28 (47%) 30 (47%) .280 2.54
.724 3.65
%) 11 (20%) 7 (13%)
%) 21 (37%) 17 (31%)
%) 24 (43%) 31 (56%)
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FIGURE 1 Cost‐effectiveness planes. (A) Meaning‐centered group
psychotherapy for cancer survivors (MCGP‐CS) compared with care‐
as‐usual (CAU); (B) MCGP‐CS compared with supportive group
psychotherapy (SGP); (C) SGP compared with CAU
VAN DER SPEK ET AL. 1777(Figure 1). The same data were used to plot the acceptability curve
(see Figure S1), showing the probability that MCGP‐CS was cost‐
effective compared with CAU, for a range of willingness‐to‐pay
thresholds. Of the bootstrapped cost‐utility pairs, 74% fell in the SE
quadrant, representing the probability that MCGP‐CS is more
effective and less costly than CAU. The probability of MCGP‐CS being
more effective in gaining QALYs than CAU is 94%, and the proba-
bility that MCGP‐CS is less costly compared with CAU is 78%.
MCGP‐CS has a 78% probability of being cost‐effective if society
is willing to pay €0 for one gained QALY, this increases to 85% ata willingness‐to‐pay threshold of €10 000 and to 92% at €30 000
(see Figure S1).
The incremental costs in the comparison of MCGP‐CS to SGP,
were €−53 (95% CI, −1826 to 1979), and the incremental effects were
.029 (95% CI, −.012 to .070). Of the bootstrapped cost‐utility pairs,
49% fell in the SE quadrant, representing the probability that MCGP‐
CS is more effective and less costly than SGP. The probability of
MCGP‐CS being more effective in gaining QALYs than SGP is 91%,
and the probability that MCGP‐CS is less costly compared with
SGP is 53% (Figure 1). MCGP‐CS has a 52% probability of being
cost‐effective if society is willing to pay €0 for one gained QALY, this
increases to 63% at €10 000 and to 77% at €30 000 (see Figure S1).
Between SGP and CAU, the incremental costs were €−759 (95%
CI, −2625 to 972), and the incremental effects were .004 (95% CI,
−.036 to.044). Of the bootstrapped cost‐utility pairs, 49% fell in the
SE quadrant, representing the probability that SGP is more effective
and less costly than CAU. The probability of SGP being more effective
in gaining QALYs than CAU is 58%, and the probability that SGP is less
costly compared with CAU is 79% (Figure 1). SGP has an 80% proba-
bility of being cost‐effective if society is willing to pay €0 for one
gained QALY, this does not increase if society is willing to pay more
(Figure S1).3.4 | Sensitivity analyses
To assess the robustness of findings, additional analyses were per-
formed (Table 2). The complete case and extra intention‐to‐treat anal-
yses showed that MCGP‐CS had a probability of 54% to 78% to be
less costly and more effective compared with CAU, that MCGP‐CS
had a probability of 55% to 64% to be less costly and more effective
compared with SGP, and that SGP had a probability of 22% to 47%
to be less costly and more effective compared with CAU. In addition,
adjusting for differences in variables at baseline did not influence
incremental costs or incremental effects with more than 20%. These
findings indicate that the results of the base case intention‐to‐treat
CUA are robust.4 | DISCUSSION
This is the first economic evaluation of a meaning‐focused interven-
tion for cancer patients, incorporating both medical costs and
nonmedical costs (eg, productivity losses and informal care costs).
Evidence of the superiority of MCGP‐CS over CAU and SGP, in terms
of efficacy, was already found in a previous study.7 The cost‐utility
analyses in the present study show that MCGP‐CS is likely to be
cost‐effective compared with both control groups, meaning that there
is a positive ratio between the costs and gains of MCGP‐CS. The
results indicate that MCGP‐CS is more effective and less costly com-
pared with CAU and showed that MCGP‐CS is probably more effec-
tive, but not less costly than SGP. It was found that MCGP‐CS has a
78% probability of being cost‐effective, compared with CAU; if soci-
ety is willing to pay €0 for one gained QALY, this increases to 85%
at €10 000/QALY and to 92% at €30 000/QALY. Commonly accepted
willingness‐to‐pay thresholds are €20 000 to €30 000 per QALY.21,22
1778 VAN DER SPEK ET AL.Economic evaluations of psychosocial interventions for cancer
patients up until now are scarce; most of these studies find promising
results showing that psychosocial interventions for cancer patients
can be good value for money.5,23-25 As this is the first study to assess
the cost‐utility of a meaning‐focused group intervention for cancer
survivors from a societal perspective, we are not able to directly com-
pare our findings with previous studies. One economic evaluation has
been conducted on supportive‐expressive group therapy (SEGT),
which focuses on emotional expression, social support, coping, and
also on existential issues, including meaning.26 This study among met-
astatic breast cancer patients did not find evidence for lower costs in
the intervention group, which is in contrast to our findings. A possible
explanation is that our study used a broader scope of medical costs
and included productivity costs and informal care costs. Also, our
study targeted cancer survivors, while the SEGT‐study targeted
advanced cancer patients.4.1 | Study limitations
The present study has some limitations. First, the estimates of medical
costs outside the hospital were based on self‐report, which might be
less accurate than data from public registers. However, there is empir-
ical support that medical self‐report data are comparable to register
collected data.27 Also, by using self‐report data, we were able to
measure important costs from a societal perspective, such as informal
care costs and productivity losses due to presenteeism, which are not
registered in public registers. Second, the assessments at all time
points did not fully cover the actual costs made during the study
period, so for the cost calculation, we partly had to rely on estimates.
However, we conducted several sensitivity analyses around these esti-
mates, showing that the findings were robust. Third, these results are
based on the Dutch situation and cost prices, which are not necessar-
ily generalizable to other countries. Finally, the results need to be
interpreted with caution, because the differences in QALYs gained
and total costs between the 3 conditions did not reach statistical sig-
nificance, and the trial was underpowered to detect such differences.
For this reason, a probabilistic approach to economic analyses along-
side trials is applied, rather than reliance upon significance levels.284.2 | Future directions
We have some recommendations for future studies. Economic evalu-
ations are scarce and often underpowered, which calls for more stud-
ies, including meaning‐focused treatments, to obtain better insight
into to what extent these interventions for cancer patients are eco-
nomically beneficial. Furthermore, future studies should take total
costs from a societal perspective into account. In this study, we took
patient‐related costs into account, including informal care costs.
Besides these costs, however, there might be an effect on costs made
by caregivers as well (eg, productivity losses due to caregiving, or
increased health care use due to caregiving burden). It would be inter-
esting if future economic evaluations on psychosocial interventions
would take costs made by caregivers into account, to give a more
complete insight in the value for money of these interventions.5 | CONCLUSIONS
The results of this study show that MCGP‐CS is more effective and
less costly than CAU, while it is probably more effective and equally
expensive, compared with SGP. More research on the economic ben-
efits of psychosocial interventions in oncology, from a societal per-
spective, are needed.
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